PharmaSource Podcast

David Caron, Senior Vice-President of CMC, AL102 at Immunome, shares why choosing the right CDMO partner can make or break a biotech’s development timeline: “For biotechs, the main business challenge is to do right the first time. To do this, we need to look at the risks related to each activity.” David Caron brings over three decades of pharmaceutical industry experience across multiple biotechs, with expertise spanning from bench formulation to senior leadership roles. His background includes extensive work with various dosage forms and regulatory requirements across EU and US markets. In this latest episode of the PharmaSource podcast David shares crucial insights on how emerging biotechs can optimize their CDMO partnerships, manage costs effectively, and align CMC strategy with business objectives. David Caron will be sharing advice about how to overcome biotech CMC challenges at CDMO Live 2025. Book your ticket here Read the interview here

Dr. Avencia Sánchez-Mejías is CEO and co-founder of Integra Therapeutics, a Barcelona-based biotech company developing next-generation gene-editing tools. With a background in molecular biology and clinical genetics, she brings over 15 years of experience in genetic therapy research across Europe, the US, and Asia. In this exclusive interview, Avencia shares insights on transitioning from academia to entrepreneurship, building a sustainable biotech company, and leveraging strategic partnerships to bring innovative gene therapy solutions to market. “Having a technology that can address genetic conditions and new diseases that today are not treatable, can have a huge impact. Not only for the patient but also for the cost of the health system.”, she says. One of Integra’s most significant strategic decisions was expanding beyond being purely a platform technology company to developing their own therapeutic products. This transition required careful consideration of sustainable growth and market validation strategies. “This is probably one of the most strategic decisions that we had to take,” Avencia explains. “We think hard and long on which first indication should be to be successful. It also changed the type of company that we were. We were very technological, and now we are building therapeutic products. So the kind of talent that you need also changes.” Read full article

"The reality is, we have a lot of CDMOs don't they really know what they're getting into" says Herman Bozenhardt Herman Bozenhardt, a pharmaceutical manufacturing consultant with decades of experience in facility design and operations, brings a wealth of knowledge from his work with numerous pharmaceutical companies and contract manufacturers. His expertise spans from traditional small molecule drugs to complex biologics and potent compounds. In the latest PharmaSource podcast episode, Herman shares his candid thoughts on the challenges facing the pharmaceutical manufacturing industry, particularly in the rapidly growing field of Antibody-Drug Conjugates (ADCs). He explains why many Contract Development and Manufacturing Organizations (CDMOs) may not be adequately prepared to handle these complex and potent compounds. https://pharmasource.global/content/podcast/adc-manufacturing-why-herman-bozenhardt-believes-only-5-cdmos-are-fit-for-purpose/

GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2029. However, their rapid rise raises important questions about resource allocation in pharmaceutical development and manufacturing, as well as affecting the dynamics between patients, healthcare providers, and biopharma. In the latest episode of the PharmaSource podcast, Ben Locwin, Chief Scientist at Black Diamond Networks, explains that GLP-1 drugs represent a significant breakthrough in the treatment of obesity and diabetes and the unintended consequences they are bringing to the industry. Read the article here